Affimed Appoints Dr. Wolfgang Fischer as Chief Operating Officer

14-Sep-2017 - Affimed N.V. announced the appointment of Dr. Wolfgang Fischer as Chief Operating Officer. "We are very pleased that Dr. Wolfgang Fischer has joined our management team as COO," said Dr. Adi Hoess, Chief Executive Officer of Affimed. "With his solid track record in drug development and project ...

Amphivena Completes $14 Million Equity Financing and Signs Agreement with Janssen

16-Jul-2013 - Affimed Therapeutics AG announced that its subsidiary Amphivena Therapeutics Inc., a drug discovery company developing bispecific TandAb antibodies to treat hematological tumors, has successfully completed a $14 million Series A equity financing. The Series A financing was led by MPM Capital, ...

Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study

17-Nov-2010 - Affimed Therapeutics AG announced that the first patients with Hodgkin's Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin's Lymphoma patients across two centers in Europe and the ...

Affimed Therapeutics AG expands clinical development team

10-Mar-2010 - In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG expands its development team with an experienced expert. Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical development programs at ...

Affimed joins the Molecular Imaging Technology Initiative

BMBF awards Affimed a funding grant of €550K

11-Feb-2009 - Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education and Research (“BMBF”). Affimed ...

Affimed appoints Chief Business Officer

10-Jun-2008 - Affimed Therapeutics AG announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer. Dr. Lang joins Affimed from Scil Technology where he was Vice President of Corporate Development. At Scil Technology, he was responsible for the commercial development of a portfolio of ...

Affimed validates antibody target for cancer metastasis

14-May-2008 - Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other therapeutic interventions. The ...

Affimed's fully human anti-thrombosis antibody shows in vivo efficacy with reduced side effects

07-Dec-2006 - Affimed Therapeutics AG announced that preclinical proof of concept has been established for its anti-thrombosis product candidate. According to the company, Affimed's fully human antibody predominantly binds to the activated form of a receptor (GPIIb/IIIa) that plays a major role in the ...

XOMA and Affimed Sign Antibody Cross-License and Collaboration Agreement

05-Oct-2006 - XOMA Ltd. and Affimed Therapeutics AG have signed a cross-license and collaboration agreement for antibody-related technologies. Financial terms were not disclosed. The agreement provides XOMA with a license under Affimed's antibody library patents for antibody discovery purposes, as well as ...

Affimed Therapeutics and Biopharma Unit of Syngenta Enter Into Agreement to Co-develop Tandabs

08-Nov-2004 - Heidelberg. Affimed Therapeutics AG, a Heidelberg, Germany-based drug development company, has signed a partnership agreement with the biopharmaceutical unit of Syngenta AG of Basel, Switzerland to co-develop one of Affimed's proprietary Tandab antibodies. Tandabs recruit the body's immune ...